首页> 外文期刊>Antiviral Research >Construction of a hepatitis B virus neutralizing chimeric monoclonal. antibody recognizing escape mutants of the viral surface antigen (HBsAg)
【24h】

Construction of a hepatitis B virus neutralizing chimeric monoclonal. antibody recognizing escape mutants of the viral surface antigen (HBsAg)

机译:乙型肝炎病毒中和嵌合单克隆的构建。 识别病毒表面抗原(HBsAg)的逃逸突变体

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis B virus (HBV) infection is a global burden on the health-care system and is considered as the tenth leading cause of death in the world. Over 248 million patients are currently suffering from chronic HBV infection worldwide and annual mortality rate of this infection is 686000. The "a" determinant is a hydrophilic region present in all antigenic subtypes of hepatitis B surface antigen (HBsAg), and antibodies against this region can neutralize the virus and are protective against all subtypes. We have recently generated a murine anti-HBs monoclonal antibody (4G4), which can neutralize HBV infection in HepaRG cells and recognize most of the escape mutant forms of HBsAg. Here, we describe the production and characterization of the chimeric human-murine antibody 4G4 (c-4G4). Variable region genes of heavy and light chains of the m-4G4 were cloned and fused to constant regions of human kappa and IgG1 by splice overlap extension (SOE) PCR. The chimeric antibody was expressed in Chinese Hamster Ovary (CHO)-K1 cells and purified from culture supernatant. Competition ELISA proved that both antibodies bind the same epitope within HBsAg. Antigen-binding studies using ELISA and Western blot showed that c-4G4 has retained the affinity and specificity of the parental murine antibody, and displayed a similar pattern of reactivity to 13 escape mutant forms of HBsAg. Both, the parental and c-4G4 showed a comparably high HBV neutralization capacity in cell culture even at the lowest concentration (0.6 mu g/m1). Due to the ability of c-4G4 to recognize most of the sub-genotypes and escape mutants of HBsAg, this antibody either alone or in combination with other anti-HBs antibodies could be considered as a potent alternative for Hepatitis B immune globulin (HBIG) as an HBV infection prophylactic or for passive immunotherapy against HBV infection. (C) 2017 Elsevier B.V. All rights reserved.
机译:乙型肝炎病毒(HBV)感染是卫生保健系统的全球负担,被认为是世界上死亡的第十个主要原因。超过2.48亿患者目前患有慢性HBV感染,并且这种感染的年死亡率为686000.“A”决定因素是一种亲水区,其丙型肝炎表面抗原(HBsAg)的所有抗原亚型,以及对该区域的抗体存在于抗原亚型中可以中和病毒并对所有亚型进行保护。我们最近产生了鼠抗HBs单克隆抗体(4G4),其可以中和HBV感染在肝细胞中并识别大部分逃生突变形式的HBsAg。在此,我们描述了嵌合人鼠抗体4G4(C-4G4)的生产和表征。通过剪接重叠延伸(SOE)PCR克隆和融合M-4G4的重和轻链的可变区域基因并融合人Kappa和IgG1的恒定区域。嵌合抗体在中国仓鼠卵巢(CHO)-K1细胞中表达并从培养上清液中纯化。竞争ELISA证明,两种抗体都在HBsAg中结合了相同的表位。使用ELISA和Western印迹的抗原结合研究表明,C-4G4保留了父母鼠抗体的亲和力和特异性,并显示了与13次逃生突变形式的HBsAg相似的反应性模式。既然,父母和C-4G4也表明,即使以最低浓度(0.6μg/ m1),也表明细胞培养中具有相当高的HBV中和能力。由于C-4G4识别HBsAg大多数亚基因型和逃生突变体的能力,这种抗体单独或与其他抗HBS抗体组合可以被认为是乙型肝炎免疫球蛋白(HBIG)的有效替代方案作为HBV感染预防或被动免疫疗法免受HBV感染。 (c)2017 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号